CD109 Antibody (B-9): sc-271039
- CD109 Antibody (B-9) is a mouse monoclonal IgG2a κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 957-1041 mapping within an internal region of CD109 of human origin
- recommended for detection of CD109 of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for CD109 Antibody (B-9) for WB applications. This reagent is now offered in a bundle with CD109 Antibody (B-9) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD109 Antibody (B-9) is a mouse monoclonal IgG2a antibody that detects CD109 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD109 is a glycosylphosphatidylinositol (GPI)-linked cell surface glycoprotein that plays a crucial role in various biological processes, particularly in the context of cancer. CD109 is a member of the α-Macroglobulin/C3, C4, C5 family of thioester-containing proteins and is notably expressed in CD34+ acute myeloid leukemia cell lines, activated T lymphoblasts, activated platelets, endothelial cells, and certain carcinomas, including lung and esophageal squamous cell types. CD109 exhibits characteristics of a cancer-testis antigen, which can be pivotal in cancer immunotherapy. Additionally, CD109 carries the platelet-specific Gov antigen system, which is essential for understanding complications related to platelet transfusions, such as transfusion refractoriness and neonatal alloimmune thrombocytopenia. Anti-CD109 antibody (B-9) effectively targets CD109, making this antibody a valuable tool for researchers investigating CD109′s role in hematological malignancies and other related conditions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD109 Antibody (B-9) References:
- CD109 is a component of exosome secreted from cultured cells. | Sakakura, H., et al. 2016. Biochem Biophys Res Commun. 469: 816-22. PMID: 26707640
- CD109: a multifunctional GPI-anchored protein with key roles in tumor progression and physiological homeostasis. | Mii, S., et al. 2019. Pathol Int. 69: 249-259. PMID: 31219232
- CD109 regulates the inflammatory response and is required for the pathogenesis of rheumatoid arthritis. | Song, G., et al. 2019. Ann Rheum Dis. 78: 1632-1641. PMID: 31455659
- CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells. | Hatsuzawa, Y., et al. 2020. Pancreatology. 20: 493-500. PMID: 32007357
- CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity. | Filppu, P., et al. 2021. JCI Insight. 6: PMID: 33986188
- The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β. | Tanabe, M., et al. 2022. Leukemia. 36: 847-855. PMID: 34743190
- CD109 on Dendritic Cells Regulates Airway Hyperreactivity and Eosinophilic Airway Inflammation. | Aono, Y., et al. 2023. Am J Respir Cell Mol Biol. 68: 201-212. PMID: 36215676
- CD109 Pumps Up Type Two Dendritic Cells for Allergic Responses in the Airways. | Nakano, H. and Cook, DN. 2023. Am J Respir Cell Mol Biol. 68: 127-128. PMID: 36264767
- CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis. | Kim, JS., et al. 2023. Int J Mol Sci. 24: PMID: 37373457
- CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling. | Naoi, H., et al. 2024. J Immunol. 212: 1221-1231. PMID: 38334455
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD109 Antibody (B-9) | sc-271039 | 200 µg/ml | $322.00 | |||
CD109 Antibody (B-9): m-IgG Fc BP-HRP Bundle | sc-540196 | 200 µg Ab; 10 µg BP | $361.00 |